Abstract
Background:Filgotinib (FIL), an oral selective JAK1 inhibitor, has shown efficacy and safety in multiple phase 3 studies in adults with moderately-to-severely active rheumatoid arthritis (RA), including those who are naïve...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have